Cisatracurium Besylate is a bisbenzyltetrahydroisoquinolinium that has effect as a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively inanesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation duringsurgery or mechanical ventilation. It shows intermediate duration of action. Cisatracurium is one of the ten isomers of the parent molecule, atracurium. Moreover, cisatracurium represents approximately 15% of the atracurium mixture.
For this API product, we have got Chinese local GMP certificate, and US-DMF of this API is available. EDMF is submitted in schedule. It was launched into Asian and South American market.
For this Finished Dose Form, Cisatracurium Besylate for Injection, files have been submitted to multiple authorities of various countries for approval. It is the one of key products in our company’s anaesthetic products’ line. It was submitted to US FDA for approval in 2012 and expected approval and launch date is 2017.